Figure 5.

Median change in plasma viral load (pVL) from baseline in patients with CCR5-using (R5) virus stratified by weighted optimized background therapy susceptibility score (wOBTss). Maraviroc-treated patients identified as having R5 virus at screening by genotyping (light gray lines) or Trofile (black lines). Patients identified at screening at having R5 virus by either method who also had wOBTss >2 (n = 68 and n = 80, respectively) showed the largest pVL decreases from baseline. Patients with wOBTss 1–2 (n = 151 and n = 197) showed intermediate pVL decreases, and patients with wOBTss ≤1 (n = 392 and n = 463) showed poorer changes in pVL. The wOBTss >2, 1–2, and ≤1 groups are indicated by thin, intermediate, and thick lines, respectively.